## What is claimed is:

- 1. A drug dosage form comprising a thyroid hormone and at least one pharmaceutically acceptable excipient prepared under conditions of low compression.
- 2. The drug dosage form of claim 1 comprising a capsule.
- 3. The drug dosage form of claim 1 comprising a capsule formed of hydroxypropyl methylcellulose.
- 4. The drug dosage form of claim 1 wherein the hormone is contained in solid form within a capsule.
- 5. The drug dosage form of claim 1 wherein the form is subjected to no compression in excess of about 10,000 psi/g.
- 6. The drug dosage form of claim 1 wherein the form is subjected to no compression in excess of about 5,000 psi/g.
- 7. The drug dosage form of claim 1 wherein the form is subjected to no compression in excess of about 2,000 psi/g.

- 8. The drug dosage form of claim 1 wherein the excipient is hydroxypropyl methylcellulose, carboxymethyl cellulose, microcrystalline cellulose, amorphous silicon dioxide, magnesium stearate, starch, sodium starch glycolate, or a combination thereof.
- 9. The drug dosage form of claim 1 wherein the excipient has a residual moisture content of less than about 10% by weight.

- 10. The drug dosage form of claim 1 exhibiting improved stability to moisture-induced degradation of the hormone as compared with a tabletted form of the hormone.
- 11. The drug dosage form of claim 1 comprising a unit dosage form.
- 12. A drug dosage form comprising levothyroxine and at least one pharmaceutically acceptable excipient prepared under conditions of low compression.
- 13. The drug dosage form of claim 12 comprising a capsule.
- 14. The drug dosage form of claim 12 comprising a capsule formed of hydroxypropyl methylcellulose.
- 15. The drug dosage form of claim 12 wherein the levothyroxine is contained in solid form within a capsule.
- 16. The drug dosage form of claim 12 wherein the form is subjected to no compression in excess of about 10,000 psi/g.
- 17. The drug dosage form of claim 12 wherein the form is subjected to no compression in excess of about 5,000 psi/g.
- 18. The drug dosage form of claim 12 wherein the form is subjected to no compression in excess of about 2,000 psi/g.
- 19. The drug dosage form of claim 12 wherein the excipient is hydroxypropyl methylcellulose, carboxymethyl cellulose, microcrystalline cellulose, amorphous silicon

24.

MPCI-0024 - 22 - PATENT

dioxide, magnesium stearate, starch, sodium starch glycolate, or a combination thereof.

- 20. The drug dosage form of claim 12 wherein the excipient has a residual moisture content of less than about 10% by weight.
- 21. The drug dosage form of claim 12 exhibiting improved stability to moisture-induced degradation of the levothyroxine as compared with a tabletted form of the levothyroxine.
- 22. The drug dosage form of claim 12 comprising a unit dosage form.
- 23. The drug dosage form of claim 12 wherein the levothyroxine is purified levothyroxine.

A drug dosage form for a thyroid drug comprising the drug admixed with a substantially non-volatile, pharmaceutically acceptable oil.

- 25. The drug dosage form of claim 24 wherein the oil is an animal or vegetable oil.
- 26. The drug dosage form of claim 24 wherein said oil is olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
- 27. The drug dosage form of claim 24 wherein the oil is a mineral oil or silicone oil.
- 28. The drug dosage form of claim 24 wherein the drug oil admixture is present within a capsule.
- 29. The drug dosage form of claim 24 wherein the drug oil admixture is present within a soft shell capsule.

MPCI-0024 - 23 - PATENT

- 30. The drug dosage form of claim 24 wherein the drug oil admixture is present within a specially sealed hard-shell capsule.
- 31. The drug dosage form of claim 24 wherein at least some of the drug oil admixture is adsorbed on a pharmaceutically acceptable excipient.
- 32. The drug dosage form of claim 24 wherein the excipient having the drug oil admixture adsorbed thereupon is within a capsule.
- The drug dosage form of claim 24 wherein the excipient having the drug oil admixture adsorbed thereupon is within a tablet.
- A drug dosage form for levothyroxine comprising the levothyroxine admixed with a substantially non-volatile, pharmaceutically acceptable oil.
- 35. The drug dosage form of claim 34 wherein the oil is an animal or vegetable oil.
- 36. The drug dosage form of claim 34 wherein said oil is olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
- 37. The drug dosage form of claim 34 wherein the oil is a mineral oil or silicone oil.
- 38. The drug dosage form of claim 34 wherein the levothyroxine oil admixture is present within a capsule.
- 39. The drug dosage form of claim 34 wherein the levothyroxine oil admixture is present within a soft shell capsule.

## oomsooys ...casoo

- 40. The drug dosage form of claim 34 wherein the levothyroxine oil admixture is present within a specially sealed hard-shell capsule.
- 41. The drug dosage form of claim 34 wherein at least some of the levothyroxine oil admixture is adsorbed on a pharmaceutically acceptable excipient.
- 42. The drug dosage form of claim 34 wherein the excipient having the levothyroxine oil admixture adsorbed thereupon is within a capsule.
- 43. The drug dosage form of claim 34 wherein the excipient having the levothyroxine oil admixture adsorbed thereupon is within a tablet.
- 44. The drug dosage form of claim 34 wherein the levothyroxine is purified levothyroxine.
- A drug dosage form for a thyroid drug comprising the drug and a pharmaceutically acceptable excipient admixed with a substantially non-volatile, pharmaceutically acceptable oil.
  - 46. The drug dosage form of claim 45 wherein the oil is an animal or vegetable oil.
  - 47. The drug dosage form of claim 45 wherein said oil is olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
  - 48. The drug dosage form of claim 45 wherein the oil is a mineral oil or silicone oil.
  - 49. The drug dosage form of claim 45 wherein the thyroid drug and the excipient oil admixture are present within a capsule.

MPCI-0024 - 25 - PATENT

- 50. The drug dosage form of claim 45 wherein the thyroid drug and the excipient oil admixture are present within a tablet.
- A drug dosage form for levothyroxine comprising the levothyroxine and a pharmaceutically acceptable excipient admixed with a substantially non-volatile, pharmaceutically acceptable oil.
- 52. The drug dosage form of claim 51 wherein the oil is an animal or vegetable oil.
- 53. The drug dosage form of claim 51 wherein said oil is olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
- 54. The drug dosage form of claim 51 wherein the oil is a mineral oil or silicone oil.
- 55. The drug dosage form of claim 51 wherein the levothyroxine and the excipient oil admixture are present within a capsule.
- 56. The drug dosage form of claim 51 wherein the levothyroxine and the excipient oil admixture are present within a tablet.
- 57. The drug dosage form of claim 51 wherein the levothyroxine is purified levothyroxine.
- A drug dosage form comprising a thyroid drug admixed with a pharmaceutically acceptable oil together with a first pharmaceutically acceptable excipient admixed with a second pharmaceutically acceptable oil.
- 59. The drug dosage form of claim 58 wherein the first and the second pharmaceutically acceptable oils are, independently, an animal or vegetable oil.

- 60. The drug dosage form of claim 58 wherein the first and the second pharmaceutically acceptable oils are, independently, olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
- 61. The drug dosage form of claim 58 wherein the first and the second pharmaceutically acceptable oils are, independently, a mineral oil or silicone oil.
- 62. The drug dosage form of claim 58 wherein the drug oil admixture and the excipient oil admixture are present within a capsule.
- 63. The drug dosage form of claim 58 wherein the drug oil admixture and the excipient oil admixture are present within a tablet.
- A drug dosage form comprising levothyroxine admixed with a first pharmaceutically acceptable oil together with a pharmaceutically acceptable excipient admixed with a second pharmaceutically acceptable oil.
- 65. The drug dosage form of claim 64 wherein the first and the second pharmaceutically acceptable oils are, independently, an animal or vegetable oil.
- 66. The drug dosage form of claim 64 wherein the first and the second pharmaceutically acceptable oils are, independently, olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.
- 67. The drug dosage form of claim 64 wherein the first and the second pharmaceutically acceptable oils are, independently, a mineral oil or silicone oil.

MPCI-0024 - 27 - PATENT

- 68. The drug dosage form of claim 64 wherein the levothyroxine oil admixture and the excipient oil admixture are present within a capsule.
- 69. The drug dosage form of claim 64 wherein the levothyroxine oil admixture and the excipient oil admixture are present within a tablet.
- 70. The drug dosage form of claim 64 wherein the levothyroxine is purified levothyroxine.
- A drug dosage form comprising a thyroid hormone and at least one pharmaceutically acceptable hydrophobic powder.
- 72. The drug dosage form of claim 71 wherein the hydrophobic powder is triturated directly with the thyroid hormone.
- 73. The drug dosage form of claim 71 wherein the hydrophobic powder is magnesium stearate.
- 74. A drug dosage form comprising levothyroxine and at least one pharmaceutically acceptable hydrophobic powder.
- 75. The drug dosage form of claim 74 wherein the hydrophobic powder is triturated directly with the levothyroxine.
- 76. The drug dosage form of claim 74 wherein the hydrophobic powder is magnesium stearate.
- 77. The drug dosage form of claim 74 wherein the levothyroxine is purified levothyroxine.

**MPCI-0024** 

A method for administering a thyroid hormone to a patient comprising providing a unit dose of the hormone which has not been processed employing high compression.

A method for administering levothyroxine to a patient comprising providing a unit dose of the levothyroxine which has not/been processed employing high compression.

A method for administering a thyroid hormone to a patient comprising providing a unit dose of the thyroid hormone admixed with a substantially non-volatile, pharmaceutically acceptable oil.

- 81. The method of claim 80 wherein the thyroid hormone - oil admixture is present within a capsule.
- 82. The method of claim 80 wherein the thyroid hormone - oil admixture is adsorbed on a pharmaceutically acceptable excipient.
- A method for administering levothyroxine to a patient comprising providing a unit dose of the levothyroxine admixed with a substantially non-volatile, pharmaceutically acceptable oil.
- 84. The method of claim 83 wherein the levothyroxine - oil admixture is present within a capsule.
- 85. The method of claim 83 wherein the levothyroxine - oil admixture is adsorbed on a pharmaceutically acceptable excipient.

A method for administering a thyroid hormone to a patient comprising providing a unit dose of the thyroid hormone and a pharmaceutically acceptable excipient admixed with a substantially non-volatile, pharmaceutically acceptable oil.

A method for administering levothyroxine to a patient comprising providing a unit dose of the levothyroxine and a pharmaceutically acceptable excipient admixed with a substantially non-volatile, pharmaceutically acceptable oil.

A method for administering a thyroid hormone to a patient comprising providing a unit dose of the thyroid hormone and at least one pharmaceutically acceptable hydrophobic powder.

A method for administering levothyroxine to a patient comprising providing a unit dose of the levothyroxine and at least one pharmaceutically acceptable hydrophobic powder.

oderor ezenese

odd) Ad